MRKRShareholder,True,2019-05-21 14:33:00,5.754,MRKR I saw this on another boardfor what its worth Note from Nomura MRKR Investor Dinner with Management Quick Note On Thursday May 16 we hosted an investor dinner with MRKR Dr Ann Leen CSO and Dr Mythili Koneru Sr VP of Clinical Development represented MRKR Here we highlight key takeaways from our dinner Pancreatic 3Q19 likely data on up to ten patients in Arm A six patients in Arm Bthree patients in Arm C Dr Leen is excited for early data but Arm A may be especially hard to parse for MulitTAA efficacy since it includes concurrent chemoHowever conversion from progressive disease to SD or PR or CR would be profound in this patient population even in context of background chemo We believe activity in pancreatic cancer of a T cellbased therapy would be strongly supportive of activity in other solid tumors
analyst_ratings,,2019-05-21 13:36:00,5.67,MRKR has 4 buy ratings 0 sell ratings and 0 hold ratings blueequityiosymbolMRKRR
investor_sentiment,,2019-05-21 11:57:00,5.72,Sentiment for MRKR out of 4 total scores 100 is positive and 0 is negative blueequityiosymbolMRKRS
